Home › Myasthenia Gravis › Tennessee
Myasthenia Gravis clinical trials in Tennessee
10 studies for Myasthenia Gravis are looking for participants at sites in Tennessee.
Cities in Tennessee
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Neurology Clinic, PC, Cordova
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT07217587ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Erlanger Health System, Chattanooga
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07284420ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Erlanger Health System, Chattanooga
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07673627ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Erlanger Health System, Chattanooga
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07294170Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Erlanger Health, Inc. - 1123255, Chattanooga
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06463587A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
- Ut Erlanger Neurology, Chattanooga
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07501702Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1021, Memphis
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Jul 30, 2026 · NCT07039916A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
- Research Site, Knoxville
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT07221838Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Chattanooga
- Clinical Trial Site, Knoxville
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT04202341The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
- The University of Tennessee Medical Center, Knoxville
- Vanderbilt Health, Nashville
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Apr 11, 2025 · NCT05564936From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.